Ligases Enzyme Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Ligases Enzyme Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The ligases enzyme market is anticipated to record a CAGR of nearly 5.5% during the forecast period (2022-2027).

The Covid-19 pandemic had an adverse effect on the ligases enzyme market. However, many research studies provide insight into the applications of ligases enzyme against Covid. For instance, HECT-E3 ligase family members like NEDD4 and WWP1 interact with and ubiquitylate the SARS-CoV-2 Spike protein, according to a research report published in April 2021 under the title "Inhibition of HECT E3 ligases as a possible therapy for COVID-19." In addition, original samples taken from COVID-19-infected patients overexpress HECT family members. In light of the documented well-tolerated character of the Brassicaceae natural chemicals, the HECT family members of E3 ligases are thus potentially novel biomarkers for COVID-19 as well as new possible targets of therapeutic strategy easily tested in clinical trials. Such studies are expected to increase market growth in the future.

Ligase, also known as synthetase, is an enzyme that catalyzes the production of a new chemical link between two big molecules. It uses adenosine triphosphate (ATP) to form bonds and is used in recombinant DNA cloning to join restriction endonuclease fragments that have annealed. Thus, due to its advantages it is used in providing diagnosis and therapeutics for multiple disorders such as tuberculosis. The burden of infectious diseases across the world is increasing, which is resulting in the rising focus on diagnosis and treatment of the same. The Center for Disease Control and Prevention (CDC) estimated that in 2020, there were approximately 7,174 new tuberculosis cases discovered in the United States, translating to a rate of 2.2 per 100,000 people. Thus, the high prevalence rate of people with tuberculosis surges the demand for its diagnosis, thereby, driving the ligases enzyme market. A world health organization (WHO) survey found that between January 24 and February 6, 2022, 12,368 people tested positive for influenza viruses, with 8,423 (68.1%) being categorized as influenza A and 3,945 (31.9%), as influenza B. There were 2,483 (93.6%) influenza A viruses and 171 (6.4%) influenza A(H1N1)pdm09 subtypes (H3N2). As a result, there is a significant demand for more technologically improved items, which could propel the market under study over the projection period. Similarly, ligases enzyme are used to treat cancer. For instance, a research study titled "The Role of SUMO E3 Ligases in Signaling Pathway of Cancer Cells" published in March 2022 stated that small ubiquitin-like modifier (SUMO)ylation is a reversible post-translational modification that plays an essential role in numerous aspects of cell physiology, including cell cycle regulation, DNA damage repair, and protein trafficking and turnover, both of which are crucial for cell homeostasis. Thus, such research studies are expected to increase market growth. Hence, due to the aforementioned factors, the market is expected to grow in the future.

However, the risk of high sensitivity of the enzyme is expected to hinder the market growth.

Key Market TrendsPolymerase Chain Reaction Segment Dominates the Market and is Expected to Continue the Same during the Forecast Period

Polymerase chain reaction (PCR) is expected to dominate of the ligases enzyme market through the forecast period. PCR involves a thermostable ligase to join two probes or other molecules together. According to GLOBOCAN 2021, the new cancer cases that were diagnosed accounted for 19.3 million in 2021 globally. Similarly, according to Global Cancer Observatory, In 2020, around 1.2 million young adults (ages 20-39) were diagnosed with cancer worldwide, with 360,000 dying as a result. In 2020, 320,000 young individuals in nations with a high Human Development Index (HDI) were diagnosed with cancer. Collaboration is another factor in market growth. One of the market leaders in Germany, QIAGEN NV, announced in May 2021 a global partnership with Mirati Therapeutics Inc. to advance the development of a tissue-based KRAS companion diagnostic to detect individuals with malignancies that carry the KRASG12C mutation. The intended companion diagnosis would add to QIAGEN's therascreen KRAS testing lineup for the Rotor-Gene Q MDx instrument, which is based on real-time qualitative PCR. Additionally, the Indian Finance Minister suggested allocating Rs 2.23 lakh crore for health and wellbeing in the Union Budget 2021–22. This represents a 137% increase over the Rs 94,452-crore projected expenditure for healthcare in the current fiscal, and it will significantly alter the Indian healthcare system, particularly through the improvement and modernization of the current diagnostic equipment in government hospitals. For instance, the use of PCRs was extremely limited before COVID-19, but since that there has been a sharp increase in the number of government hospitals and laboratories. Given the potential increase in PCR installations, this situation has helped to accelerate the market's growth.

North America Dominates the Market and is Expected to Continue the Same during the Forecast Period

North America is a prominent market due to the well-established end-user industries, such as molecular biology laboratories, research institutes, and pharmaceutical companies. The high scope for R&D activities in major countries is driving regional growth. According to the American Cancer Society, in 2021 the estimated new numbers of cancer cases were 1.9 million in the United States. And in 2022 the same source projected that the new number of cancer cases will be 1.9 million in the United States. Collaboration is another element that contributes to market expansion. For instance, Beckman Coulter Life Sciences and Illumina sign a contract for the application development of the Biomek NGeniuS System in February 2022. Innovations like a reagent input carousel, which reduces the manual transfer of reagents, as well as an integrated heat cycler and labware delivery system, cut down on hands-on time. Such a partnership will support the market and boost growth. A research report by Rosa Gloria Rebollar-Vega et al., published in the Mexican journal Revista de Investigación Clnica in May 2020, predicts that next-generation sequencing (NGS) will play a larger role in molecular diagnostics during the next few years. Additionally, improvements in sequencing technologies and a decline in sequencing prices will soon make it possible for scientists to conduct more thorough and in-depth genome studies. Thus, increasing adoption of NGS is expected to increase the consumption of ligases enzymes which is expected to increase the market growth.

Competitive Landscape

The ligases enzyme market is moderately competitive and consists of global as well as local players. Due to technological advancements, small and mid-sized companies are focusing on market penetration to grab the market share. Some of the companies that are currently present in the market are ArcticZymes, New England Biolabs, Promega Corporation, QIAGEN, and Takara Bio Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.